Key result
Transcatheter renal denervation in patients with resistant hypertension and type 2 diabetes reduced office systolic BP (-27.2 mmHg, p<0.01) and HbA1c (from 6.9% to 5.8%, p=0.04) at 6 months.
Why the study?
Does transcatheter renal denervation improve glycemic control and reduce blood pressure in patients with resistant hypertension and type 2 diabetes mellitus?
Does transcatheter renal denervation improve glycemic control and reduce blood pressure in patients with resistant hypertension and type 2 diabetes mellitus?
Mean Difference: -27.2
p-value: p=< 0.01
Transcatheter renal denervation in patients with resistant hypertension and T2DM significantly improves both blood pressure and glycemic control, particularly in those who achieve a meaningful blood pressure response.
Renal denervation was associated with HbA1c reduction in resistant hypertension and T2DM; hypothesis-generating and requires randomized confirmation before practice change.
The aim of the study was to evaluatetheglycemic control dynamics depending on degree of blood pressure (BP) reduction and dynamic of TNF-α after 6 and 12 months of Tran catheter renal denervation (TRD) of patients with true resistant hypertension (RH) and type 2 diabetes mellitus (T2DM). Material and methods. Thirty two essentially hypertensive patients with type 2 diabetes mellitus (T2DM) and resistant hypertension were included in single-arm prospective interventional study. Office BP measurement, ambulatory 24-h BP, renal Doppler ultrasound and assessment of renal function (proteinuria, creatinine, eGFR), HbА1c and fasting plasma glucose (FPG) levels, activity of TNF-α were performed at baseline and 6 and 12 months after TRD. On average, patients were taking 4 (3–6) antihypertensive drugs. None of the patients changed the antihypertensive treatments during follow-up. A 6 months follow-up was completed by 27 patients (43–75 years old, 14 male), 12 months follow-up was completed by 26 patients. Results. Renal denervation significantly reduced the systolic office BP (SBP) as well as 24-h SBP (– 27.2/–10.7 mm Hg and–13.4/–10 mm Hg, respectively, p < 0.01 after 6-month follow-up, and –31,7/–12,8 mmHg and –13.4/–10 mm Hg, respectively, p < 0.01 after 12-month follow-up) without any negative effect on renal function. The number of responders with reduction of SBP >10 mmHg according to ABPM were 56% (15/27) after 6-month and 61.5% (16/26) after 12-month follow-up. There were significant reduction of the average HbA1c levels (from (6.9 ± 1.8)% to (5.8 ± 1.5)%, p = 0.04) and nonsignificant decreasing of FPG levels (from 8.7 ± 2.8 to 7.7 ± 2.1 mmol/L, p = 0.07) after 6-month followup. Conspicuously, the responders according to ABPM had significantly higher mean dynamics of HbA1c than the non-responders after 6-month follow-up (–2.4 ± 1.9 and –0.1 ± 0.8%, p = 0.02, respectively) as well as after 12-month follow-up (–0.12 ± 0.98 and 1,26 ± 1.11%, p = 0.04 for HbA1c, and – 0.89 ± 1.9 и 0.85 mmol/L ± 1.19, p = 0.02 for FPG levels). There were significant decreasing of TNF-α after 12-monthfollow-up (from 2.21 (1.54–3.65) to 1.4 (1.11–1.47pg/ml), p = 0.007), without relation to BP and HbA1c dynamics, and response to TRD. There were not the correlations between dynamics of HbA1c and FPG levels with BP reduction and change of TNF-α after 12-month follow-up. Conclusions. Renal denervation of patients with true resistant hypertension and diabetes mellitus type 2 after 6 and 12 months was followed by improved glycemic control, BP reduction and decreasing of mean levels of TNF-α. Glycemic control improvement after the renal denervation was more expressive in the responders.
No takes yet. Share an insight, caveat, or question.
Falkovskaya et al. (2015) studied Resistant hypertension and type 2 diabetes mellitus (n=32). Transcatheter renal denervation was evaluated on Reduction in systolic office blood pressure at 6 months (MD -27.2 mm Hg, p=< 0.01). Transcatheter renal denervation in patients with resistant hypertension and type 2 diabetes reduced office systolic BP (-27.2 mmHg, p<0.01) and HbA1c (from 6.9% to 5.8%, p=0.04) at 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: